🧬 BDNF Extraction Viewer

Извлечено: 997 / 997 (100.0%) Средняя confidence: 0.13
← Назад к списку

Dieckol, a phlorotannin from Ecklonia cava, alleviates stress hormone-induced depressive-like behaviors through glucocorticoid receptor antagonism.

PMID: 41650520 · DOI: 10.1016/j.phymed.2026.157906 · Phytomedicine : international journal of phytotherapy and phytopharmacology, 2026 · Inhye Park, Jung-Eun Lee, Minji Kim, Minseok Yoon, Min Jung Kim, Min-Sun Kim, Suengmok Cho, Min Young Um
📄 Abstract

Depression imposes significant social, economic, and health burdens worldwide. Although phlorotannin-rich extract from Ecklonia cava (PS) and its active compound dieckol (DK) exhibit various biological activities, their antidepressant- and anxiolytic-like effects and underlying mechanisms remain unclear. This study investigated the antidepressant- and anxiolytic-like potential of PS and DK in a corticosterone (CORT)-induced mouse model of depression and anxiety, focusing on glucocorticoid receptor (GR) signaling. CORT-treated mice were orally administered PS or DK, and behavioral tests were performed to assess depressive- and anxiety-like behaviors. PS composition was analyzed using LC-MS/MS. Molecular docking predicted the binding of PS components to GR. GR nuclear translocation, target gene expression, and downstream signaling were examined using behavioral, molecular, and computational approaches. PS alleviated CORT-induced depressive- and anxiety-like behaviors, accompanied by reduced GR nuclear translocation, suppression of Mkp-1, and restoration of ERK-CREB-BDNF signaling. Molecular docking analysis predicted strong binding of DK to the GR ligand-binding domain. Consistently, DK reduced GR nuclear translocation and GRE binding, downregulated GR target genes (Mkp-1, Sgk-1, Fkbp5, and Bdnf), and restored ERK-CREB-BDNF signaling. In vivo, DK also improved CORT-induced behavioral deficits and normalized HPA axis activity and neurotransmitter levels. Collectively, our results suggest that DK, a major bioactive phlorotannin from E. cava, exerts antidepressant- and anxiolytic-like effects in association with modulation antagonism of GR signaling, highlighting its therapeutic potential as a natural GR-modulating agent for stress-related mood disorders.

Confidence: 0.37 · 19 полей извлечено
Идентификация (6 полей)
Target
Glucocorticoid receptor
0.95
Alt. target
GR
0.95
Protein family
Nuclear receptor family
0.90
Functional class
Ligand-activated transcription factor
0.90
Subcellular loc.
Cytoplasm and nucleus
0.85
Isoforms (metab/obesity)
—
0.00
Механизм действия (21 полей)
Mechanism
glucocorticoid receptor antagonism
0.95
Mutations (obesity/lean)
—
0.00
Activity (obesity)
—
0.00
Activity temporal
—
0.00
Energy balance
—
0.00
Appetite
—
0.00
Fat metabolism
—
0.00
Lipolysis
—
0.00
Thermogenesis
—
0.00
Muscle metabolism
—
0.00
Inflammation
—
0.00
Glucose metabolism
—
0.00
AA metabolism
—
0.00
Hormonal pathways
modulates glucocorticoid receptor signaling, normalizes HPA axis activity
0.90
Cell death
—
0.00
Adipocyte fibrosis
—
0.00
Upstream (biochem)
corticosterone
0.85
Upstream (physiol)
stress
0.80
Downstream (biochem)
Mkp-1, Sgk-1, Fkbp5, Bdnf, ERK, CREB
0.90
Downstream (physiol)
HPA axis activity, neurotransmitter levels
0.85
PTMs
—
0.00
Экспрессия (8 полей)
Tissue expression
—
0.00
In vitro
—
0.00
In vivo
Corticosterone (CORT)-induced mouse model of depression and anxiety; behavioral tests; oral administration of PS or DK; assessment of depressive- and anxiety-like behaviors; GR nuclear translocation; target gene expression; downstream signaling; HPA axis activity; neurotransmitter levels
0.95
In silico
Molecular docking predicted binding of PS components to GR; molecular docking analysis predicted strong binding of DK to the GR ligand-binding domain
0.95
Genetic association
—
0.00
Ex vivo
—
0.00
Animal model
Corticosterone (CORT)-induced mouse model of depression and anxiety
0.95
Diet/model
Corticosterone (CORT)-induced mouse model
0.95
Клиника (11 полей)
Drug
Dieckol
0.95
Indication
Stress-related mood disorders, depression, anxiety
0.90
Patient subgroups
—
0.00
Safety concerns
—
0.00
Off-target
—
0.00
Trial stage
Preclinical
0.85
Pharma competitors
—
0.00
AE severity
—
0.00
MOA weight loss
—
0.00
Endpoints
—
0.00
Approved
False
0.90